Compare Direxion Daily TSLA Bull 2X Shares (TSLL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily TSLA Bull 2X Shares vs Viatris Inc — how do they compare? Direxion Daily TSLA Bull 2X Shares trades at $8, while Viatris Inc trades at $16.31 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Viatris Inc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| TSLL | VTRS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $23.03 | $17.86 |
52-Week Low | $6.74 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $8.15, down 0.73% on the day, with technical indicators showing a bearish trend. The ETF, which aims to deliver twice Tesla's daily returns, faces challenges as recent news highlights volatility risks for leveraged Tesla investments. Key support sits at $8 with resistance at $9, while RSI levels suggest mixed momentum signals.
The outlook remains cautious given the bearish technical signals and leveraged structure amplifying Tesla's volatility. Investment opportunities exist for short-term traders betting on Tesla rebounds, but risks include magnified losses during downturns and the structural decay of daily reset leveraged ETFs in volatile markets.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
